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Abstract: Marek’s disease virus (MDV) is the causative agent of Marek’s disease (MD), a complex
pathology of chickens characterized by paralysis, immunosuppression, and T-cell lymphomagenesis.
MD is controlled in poultry production via vaccines administered in ovo or at hatch, and these
confer protection against lymphoma formation, but not superinfection by MDV field strains. Despite
vaccine-induced humoral and cell-mediated immune responses, mechanisms eliciting systemic
protection remain unclear. Here we report the contents of serum exosomes to assess their possible
roles as indicators of systemic immunity, and alternatively, tumor formation. We examined the RNA
and protein content of serum exosomes from CVI988 (Rispens)-vaccinated and protected chickens
(VEX), and unvaccinated tumor-bearing chickens (TEX), via deep-sequencing and mass spectrometry,
respectively. Bioinformatic analyses of microRNAs (miRNAs) and predicted miRNA targets indicated
a greater abundance of tumor suppressor miRNAs in VEX compared to TEX. Conversely, oncomiRs
originating from cellular (miRs 106a-363) and MDV miRNA clusters were more abundant in TEX
compared to VEX. Most notably, mRNAs mapping to the entire MDV genome were identified in VEX,
while mRNAs mapping to the repeats flanking the unique long (IRL/TRL) were identified in TEX.
These data suggest that long-term systemic vaccine-induced immune responses may be mediated
at the level of VEX which transfer viral mRNAs to antigen presenting cells systemically. Proteomic
analyses of these exosomes suggested potential biomarkers for VEX and TEX. These data provide
important putative insight into MDV-mediated immune suppression and vaccine responses, as well
as potential serum biomarkers for MD protection and susceptibility.
Keywords: Marek’s disease; lymphoma; exosomes; vanin-1; insulin-like growth factor; acid labile
subunit (IGFALS), COL22A1; cancer-associated exosomes
1. Introduction
Marek’s disease virus (MDV) is a highly contagious alphaherpesvirus, belonging to the genus
Mardivirus-1, that is the causative agent of Marek’s disease (MD). MD is a complex pathology of
chickens characterized systemic immune suppression, paralysis, neurological signs and lesions, and
the rapid formation of CD4+ T-cell lymphomas [1]. The chicken MDV-infective cycle begins with
inhalation of infectious virus present in dander in the environment. In the lung, MDV infects the lung
epithelium and antigen presenting cells (APCs), B cells, and macrophages [2]. Infected APCs transfer
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the virus to lymphoid tissues, where the virus undergoes productive-restrictive replication in its early
target cells, which include B cells. B cells, and ostensibly other APCs, transfer MDV infection to CD4+
T cells that are the target for MDV latency and subsequent transformation.
An innate immune response mounted in response to early MDV lytic replication correlates with the
establishment of latency, primarily in CD4+ T-cells. Transformation of latently-infected CD4+ T cells is due
to expression of the MDV primary oncoprotein Meq, its splice-variant derivatives, and other MDV gene
products (vTR, RLORF4, UL36, etc.) including viral microRNAs (miRNAs) [3–6]. T-cell lymphomas arise
in various visceral and peripheral organs concomitant with profound systemic immune suppression
due to the T-regulatory-like patterning of the transformed T-cells [7]. Latently-infected and transformed
CD4+ T cells also transport the virus to the feather follicular epithelium (FFE), where the virus
undergoes fully productive replication and is dispersed into the environment as desquamated epithelial
cells (dander), where it can remain infectious for months, years, and perhaps decades.
In infected chickens, pathogenic field strains of MDV can cause a mortality of up to 100% in
unvaccinated flocks; however, commercial losses due to MD are effectively controlled by the use of
antigenically-related live attenuated vaccines. MD vaccines prevent tumor formation, but not super
infection by virulent field strains [8]. While vaccine-induced, cell-mediated immunity plays a critical
role in protection against MD and humoral immunity has a limited role in protection. Despite the
widespread use of vaccination, how these vaccines, administered either in ovo at embryonic day 18, or
via subcutaneous injection at day of hatch, pattern systemic immunity preventing tumor formation for
the duration of the host’s life remains obscure.
In this regard, critical MDV immunogens against which cell-mediated immune responses are
directed have not been fully defined, although earlier studies in JM16- and SB-1-infected chickens
implicated cell-mediated cytotoxic response towards lytic antigens such as infected cell protein 4
(ICP4), to be crucial for genetic resistance seen in B21B21 MHC haplotype, as opposed to the susceptible
B19B19 haplotype [9,10].
MDV infection in vivo occurs via cell-to-cell spread, and the mechanisms of MDV-mediated
lymphomagenesis and systemic immune suppression continue to be defined. In terms of T-cell
transformation, the MDV-encoded primary oncoprotein, Meq, is essential for tumor formation through
transactivation of v-Jun target genes by Meq-Jun heterodimers, transrepression of lytic promoters
by Meq-Meq homodimers, suppression of apoptotic pathways and the recruitment of chromatin
remodeling complexes that repress lytic replication [11,12].
In addition, MDV-encoded and -dysregulated cellular miRNA expression have been associated
with tumor formation. In particular, the MDV-encoded miR-155 homolog, miR-M4, targets numerous
cellular genes for post-transcriptional repression (e.g., CEBP, HIVEP2, BCL2L13, JARID2, and PDCD6)
and contributes to cellular transformation [13,14]. Additionally, miR-221 and -222 have been shown to
target p27Kip in the MDV-transformed MSB-1 cell line [15].
To further the understanding of MD vaccine-induced systemic protection, as well as MDV-induced
systemic immune suppression, we performed small RNA sequencing and proteomic profiling of serum
exosomes from CVI988 (Rispens)-vaccinated and protected chickens, referred to as vaccinate exosomes
(VEX), and unvaccinated tumor-bearing chickens, referred to as tumor exosomes (TEX). Exosomes are
a subset of extracellular vesicles that are typically 30–150 nm in size and are formed upon endosomal
maturation by inward invagination and reverse budding of late endosomal limiting membrane [16].
These nanovesicles contained in the lumen of late endosome are referred to as intraluminal vesicles
(ILVs), and the late endosome bearing ILVs is referred to as multi-vesicular body (MVB). Upon fusion
of MVB with plasma membrane, ILVs are secreted into the extracellular environment where they are
referred to as exosomes. These are secreted by virtually all cell types and their presence has been
confirmed in all biological fluids including blood, urine, saliva, breast milk, aqueous humor, bronchial
and peritoneal lavages, cerebrospinal and amniotic fluids. Exosomes contain biomolecules including
proteins, nucleic acids, and lipids that reflect the source cell or tissue of origin. Exosomes serve
as vehicles of intercellular and tissue communication by mediating short- or long-range horizontal
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transfer of these biomolecules. The resultant biological effect depends on the exosomal RNA and
protein content whose selective incorporation varies depending upon the physiological or pathological
state of the originating cells.
Investigation of the RNA and protein contents of VEX may indicate key immune signaling and
oncogenic networks targeted during vaccine-induced systemic protection. Similarly, the contents of TEX
may provide insight into MDV-induced immune suppression and lymphomagenesis. We hypothesize
that these exosome populations encode molecular signatures for vaccine-induced protection and
MD-induced immune suppression and tumor formation, respectively. Furthermore, since exosomes
can function in antigen presentation during viral infections, determination of the protein content of VEX
may reveal MDV target antigens against which vaccine-induced cell mediated responses are directed,
as well as potential biomarkers of vaccine-induced protection [17–19]. Alternatively, investigation of
protein content of TEX can reveal biomarkers for and mechanisms of immune suppression and tumor
formation [20].
In the present study, we report the isolation of VEX and TEX from the serum of vaccinated
and protected commercial layer chickens (VEX) and tumor-bearing layer and broiler chickens.
These exosomes were characterized according to their size, morphology, concentration, sequence
of their RNA transcriptomes (both miRNA and mRNA), the predicted mRNA targets of contained
miRNAs, their proteomes, and the pathways likely to be affected by these miRNAs and
proteins. This study represents the first in-depth transcriptomic and proteomic analyses of chicken
serum-derived exosomes during MDV infection and provides a useful framework for successful
vaccination and immunosuppression biomarker development.
2. Materials and Methods
2.1. Source of Serum Exosomes
Exosomes were purified from sera of commercial chickens used in two vaccine trials. Each
vaccine efficacy trial used a natural exposure “shedder” model of infection, as described [21]. Briefly,
chickens were obtained as unset commercial embryonated eggs (unvaccinated contacts, vaccinate
treatments), and embryonic day 14 (E14) set embryonated eggs (shedders), from commercial hatcheries
and transferred to incubators at the University of Delaware farm. All samples obtained from animals in
this study were approved by the University of Delaware Institutional Animal Care and Use Committee
under protocol 64R-2016-0, SOP1, approved 8/1/2016 (three-year protocol) to MSP.
Shedder chickens were eyedrop-vaccinated at hatch for Newcastle’s disease (NDV) and infectious
bronchitis virus (IBV), neck-tagged for identification and inoculated intra-abdominally (IA) with
200-400 PFU of vv+MDV (strain TK-2a), and placed in a colony house (trial 1, 25 chickens per house,
8 houses), or in separate pens of a pilot broiler house (trial 2, 50 chickens per pen, 4 pens). At two
weeks post-shedder placement, unvaccinated and MD-vaccinated chickens were eyedrop vaccinated
for NDV/IBV, neck-tagged for identification, and placed in contact with the shedder chickens.
The chickens used in trial 1 were HyLine W36 white leghorns (obtained from the HyLine hatchery,
Elizabethtown, PA, USA). Trial 1 consisted of a comparison of three commercial CVI988 (Rispens)
vaccines with an experimental, attenuated MDV-1 vaccine. Chickens were vaccinated subcutaneously
at hatch with 1× commercial dose (target dose 3500 PFU) of one of the four vaccines. Vaccinated
chicks were co-housed with shedder and unvaccinated chickens, provided with commercial feed and
water ad libitum, and spray-vaccinated against NDV/IBV on the 29th day post-placement. Birds were
monitored daily for MD clinical signs and moribund chickens were culled. For each house, the
target numbers of shedders, unvaccinated- and vaccinated-contact-exposed chickens were 25, 15, and
65, respectively. Surviving shedder chickens were removed at 42 days post-placement (four weeks
post-mixing with other groups), euthanized, and scored for MD lesions. The trial was terminated
at 49 days post-placement of vaccinates and remaining unvaccinated and vaccinated-chickens were
euthanized and scored for MD lesions.
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The chickens used in trial 2 were commercial broilers obtained from Mountaire Farms, Inc.
(Millsboro hatchery, Millsboro, DE, USA). Trial 2 consisted of a comparison of herpesvirus of turkeys
(HVT) commercial and experimental vaccines, administered in ovo at E18, at two dosage levels.
This study was conducted in a pilot-scale broiler house at the University of Delaware farm (maximum
capacity = 2500 broiler chickens), with the single-room being split into [4] pens separated by a central
staging area. The target numbers for each pen were: shedders (20), unvaccinated contacts (15), vaccine
treatments (total of 8 treatments, 25 per treatment) for a total of 285 chickens per pen (1140 for the entire
study). Timing for vaccine efficacy trial 2 was identical to that of trial 1 (shedders euthanized at 42 dpi,
unvaccinated and vaccinated groups terminated at 49 days post-placement). Vaccine efficacy trials
were approved by the University of Delaware IACUC and were performed under protocol #64R-2016-0.
For the purposes of exosome isolation, chickens showing clear signs of MD (red-leg, ataxia,
paralysis) were bled via cardiac puncture, immediately euthanized and scored for MD lymphomas
(trials 1 and 2). Similarly, vaccinated and visibly-protected chickens (large, lesion-free, good body
condition and coloration) were similarly bled, euthanized and scored for MD lesions (trial 1 only).
Blood samples (~10 mL) from tumor-bearing chickens were used for exosome isolation and
designated as tumor-associated exosomes (TEX). Similarly, blood samples from vaccinated and
visibly-protected chickens were used for exosome isolation and designated as vaccine-associated
exosomes (VEX). For both groups, whole blood was collected without anticoagulant using 10 cc
syringes with 18-gauge needles, and syringes were stored at 37 ◦C for 1 h followed by 4 ◦C, overnight.
Serum samples were carefully collected and stored at −80 ◦C until exosome purification.
For in-depth characterization, TEX were isolated from MD gross lesions-positive (MD+), leghorns
(n = 4) and broilers (n = 4) from efficacy trials 1 and 2, respectively. VEX were isolated from protected
leghorns (n = 4) that were scored negative for MD gross lesions (MD-), from trial 1 only. Bird neck tag
numbers of the chickens used for these studies are given in Table 1.
Table 1. Exosome Serum Sources, small RNA, microRNA (miRNA) and mRNA mapping data.
Serum
Exosome
Source
Bird
Tag#
Raw
Reads
Mapped to
Gallus
gallus
%
miRNAs
Mapped
to MDV
%
mRNAs
Mapped
to MDV
%
leghorn
VEX
BL3815 27,168,090 5,539,665 20.4 478 0.009 11,995 0.22
BL3841 16,544,388 12,264,873 74.1 224 0.002 29,586 0.24
BL3850 11,567,549 73,94,774 63.9 6895 0.09 36,084 0.49
BL3825 8,516,052 4,885,568 57.4 1864 0.04 8335 0.17
Means 15,949,020 7,563,369 47.4 2365 0.03 21,500 0.28
leghorn
TEX
OR1810 18,024,380 9,038,453 50.15 47,893 0.53 64,636 0.72
OR1760 13,826,014 8,725,701 63.11 4126 0.05 314 0.003
OR1838 26,009,675 8,559,904 32.91 4399 0.05 534 0.006
OR748 16,422,100 8,321,176 50.67 9594 0.12 56,629 0.68
Means 18,570,542 8,661,309 46.64 16,503 0.19 30,528 0.35
broiler
TEX
BL4178 15,878,894 9,747,686 61.39 22,533 0.23 57,285 0.58
BL4047 16,472,545 12,121,502 73.59 89,040 0.73 66,270 0.54
BL4062 14,407,601 9,424,620 65.41 148,011 1.57 55,003 0.58
BL4183 26,533,369 16,334,950 61.56 72,162 0.44 87,058 0.53
Means 18,323,102 11,907,190 65.0 82,937 0.70 66,404 0.55
Totals 211,370,657 112,358,872 53.16 409,687 0.36 473,729 0.42
VEX: vaccine-associated exosomes; TEX: tumor-associated exosomes; MDV: Marek’s disease virus.
2.2. Serum Exosome Purification
Exosome purification was carried out using total exosome isolation reagent (TEI, Invitrogen,
Carlsbad, CA, USA) solution according to the manufacturer’s recommendations as described
previously [22]. For small RNA sequencing experiments, serum exosomes were purified by ExoQuick
Solution (System Biosciences, Palo Alto, CA, USA), following manufacturer’s recommendations.
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2.3. Nanoparticle Tracking Analysis
The concentration and size distribution profiles of exosome particles were evaluated by tracking
their Brownian motion using a Nanosight nanoparticle tracking instrument (NS300, Malvern,
Worcestershire, UK) and analyzed with NTA 3.2 Dev Build 3.2.16 software, essentially as described [22].
The following post-acquisition analysis settings were selected: minimum detection threshold 4,
automatic blur, and automatic minimum expected particle size. Each sample was diluted 1:20 in
particle-free PBS before injecting into the instrument. During the instrument run, three 1 min videos
were recorded at camera level 12 with minimum expected particle size, track length, and blur setting,
all set to default and analyzed in batch processing mode. Analyses of representative NTA histograms
for VEX and TEX are shown in Figure 1C.
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2.4. Transmission Electron Microscopy
For TEM analyses, exosome-PBS suspensions from two randomly selected samples, one VEX (Bird
tag# BL3825; leghorn VEX) and one TEX (Bird tag# OR1760; leghorn TEX) were floated on to 400 mesh,
carbon-coated copper grids that were previously glow discharged with a PELCO easiGlow™ glow
discharge system to render the surface of the grids hydrophilic. Grids were then subjected to washes
on drops of water, and then negative stained with 2% uranyl acetate. Air-dried grids were examined
with a Zeiss Libra 120 transmission electron microscope at 120 kV, and images were acquired with
a Gatan Ultrascan 1000 2k × 2k CCD camera in the bioimaging core at the Delaware Biotechnology
Institute at the University of Delaware. For each set of analyses, at least 20 fields were imaged and
representative images are shown in results sections.
2.5. Exosomal Small RNA Sequencing
For high throughput sequencing, LC-Sciences, LLC (Houston, TX, USA) was contracted for
exosome isolation, RNA purification, library generation, sequencing, and initial bioinformatic analysis.
For sequencing of exosome small RNAs, sera from vaccine efficacy trials 1 (leghorn VEX [n = 4]
and leghorn TEX [n = 4]) and 2 (broiler TEX [n = 4]) were subject to precipitation by ExoQuick
Solution (System Biosciences), followed by loading of exosome lysate onto SeraMiR columns (System
Biosciences). Eluted RNAs were resuspended in RNAse free water. The quantity and quality of the
RNA were determined by Agilent 2100 Bioanalyzer with a total RNA Pico Chip (Agilent Technologies,
Santa Clara, CA, USA).
2.5.1. Small RNA Library Preparation
Small RNA libraries were prepared by Illumina Truseq™ Small RNA preparation kit according to
manufacturer’s instructions (Illumina, Inc., San Diego, CA, USA). Briefly, small RNAs were adaptor
ligated on both 5′ and 3′ ends, followed by reverse transcription with a 3′ adaptor primer. The resultant
complementary DNA (cDNA) products were subject to PCR enrichment using a common PCR Primer
complementary to 5′ end adaptor and a reverse primer containing a primer index on the 5′ end of the
region complementary to 3′ adaptor. The PCR enrichment step allowed library amplification along
with index bar coding to facilitate multiplexing during sequencing. The indexed libraries were PCR
purified and post PCR purified library was quantified on a Qubit 2.0 fluorometer (Invitrogen).
The purified cDNA library was subject to cluster generation on Illumina cluster station and then
sequenced on Illumina Hiseq Platform. Raw sequencing reads (~50 nt) were obtained using Illumina’s
Sequencing Control Studio software version 2.8 (SCS v2.8) following real-time sequencing image
analysis and base-calling by Illumina’s Real-Time Analysis version 1.8.70 (RTA v1.8.70). A series of
digital filters were applied to exclude unmappable low complexity reads (reads lacking a 3′ adaptor,
adaptors with greater than one mismatch, reads >32 nts after 3′ adaptor removal, reads <15 nts after
3′ adaptor removal) from the raw sequence data to obtain unique reads. The extracted sequencing
reads were stored in FastQ (fq) files, which were then used in the post processing steps by standard
data analyses pipelines, described below.
2.5.2. Small RNA seq Data Analyses
Briefly, quality control of raw reads was performed using FastQC (Babraham Bioinformatics,
London, UK), and unique reads were imported into a proprietary data analysis platform,
ACGT101-miR v4.2 (LC Sciences, Houston, TX, USA) for data analysis. Post-sequencing removal of
adaptor sequences, low-quality reads, and common RNA families (rRNA, tRNA, snRNA, snoRNA),
unique sequences of 15–32 bases were mapped to Gallus gallus precursor and mature miRNAs in
miRBase 21.0 using a BLAST search to identify known miRNAs. For the unmapped sequences, a
BLAST search was performed against the Gallus gallus reference genome, and the mapped sequences
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that contained potential hairpin RNA structures were predicted from the flanking 80-nt sequences
using RNAfold software [23,24].
2.5.3. MiRDeep2 Analyses of Precursor and Mature MDV-1 miRNAs
For determining precursor and mature miRNA reads originating from MDV-1 genome, a UNIX
shell installed with PERL-based package, miRDeep2 (version 2.0.0.7), created by Friedlander et al. [25],
was utilized. Briefly, unique reads in the FASTA (.fa) format were filtered to limit the read length to
17 bases. Next, using miRDeep2 mapper function (mapper.pl), reads comprising identical sequence
were collapsed to remove redundancy. Collapsed reads were mapped to the pRB1B reference genome
(GenBank Accession no: EF523390) with bowtie options; bowtie –f –n 0 –e 80 –l 18 –a –m 5 –best –strata.
These options correspond to non-allowance of mismatches in the seed region, allow 2 mismatches after
the seed region to account for non-templated additions, and preservation of reads that map no more
than 5 times in the genome. In addition, if mappings with 0 mismatches occurred, then mappings
with one or two mismatches were not accounted. Finally, processed reads and the mappings to the
genome were outputted in .arf format and directly inputted to the miRDeep2 module to identify
MDV-1 miRNA read numbers.
2.5.4. miRDB Prediction of miRNA Gene Targets
The set of genes targeted by each exosomal miRNA was predicted using the miRDB
online resource and analysis platform (http://www.miRDB.org//). Launched in 2008, it was
comprehensively updated where the complete set of miRNA sequences from the miRBase repository
was downloaded along with the complete set of G. gallus 3′UTR sequences contained in the NCBI
RefSeq database [26]. In addition, the miRDB target prediction algorithm, MiRTarget, which was
developed using support vector analysis of high throughput expression data, predicts conserved and
non-conserved target genes via weighting target site conservation as a high priority, but not as a strict
requirement. miRDB target scores range between 50 to 100, with a greater score indicating a greater
statistical confidence in the target prediction. Predicted targets with a score >80 were considered
to be the most confident gene predictions and were therefore used for gene ontology and pathway
enrichment analysis.
2.5.5. Gene Ontology and Pathway Enrichment Analysis
The DAVID (Database for Annotation, Visualization and Integrated Discovery) [27,28] database
was used to perform gene ontology enrichment analyses on miRDB predicted gene targets of VEX- or
TEX-upregulated miRNAs [29]. G. gallus genes were uploaded into the DAVID database and enriched
gene ontology terms and KEGG pathways were identified.
2.5.6. Geneious Mapping of Reads to the MDV Genome
Quality controlled unique reads were mapped against pRB1B reference genome (Accession no:
EF523390) to produce a contig using the Geneious (v.10) read mapper with 10% allowed gaps per read,
word length of 18, and 20% maximum mismatches per read and with structural variant, insertion, and
gap finding allowed.
2.5.7. Read Count Normalization and Comparisons
Normalization of read counts in each sample (or data set) was achieved by dividing the read counts
by a library size parameter of the corresponding sample. Reads were removed if the corresponding
maximum number of raw reads in all samples was less than 10. In a statistical test, a read was
removed if the mean value of the normalized reads of all samples involved in the test was less than
10. The differential expression of each miRNA was calculated based on the fold change observed
between different group comparisons (leghorn VEX versus TEX, and leghorn VEX versus broiler TEX).
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The “calculate expression levels” feature of Geneious was used to measure normalized expression
levels of MDV-coding regions. This feature normalizes mapped raw read count by transcript length
and sequencing depth and expressed as “reads per kilobase transcript per million mapped reads
(RPKM)”. Statistical significance between the two groups was determined by unpaired Student’s t-test.
2.6. Proteomic Analysis of Exosomes
2.6.1. Sample Preparation
For proteomic analysis, 50 µg of exosome protein from TEI-purified exosomes was submitted
to Dr. Fiona McCarthy and Mr. Ken Pendarvis at the University of Arizona Core Proteomics facility
(Keating Bioresearch Building, U. Arizona, Tucson, AZ, USA). Exosome protein purification was
performed as described by McCarthy et al. [30]. Differential detergent fractionation was performed
with digitonin followed by Triton X-100 to extract soluble and membrane associated exosomal proteins.
Protein fractions were treated with a mixture of DNase I (50U; Invitrogen) and RNase A (50 mg;
Sigma-Aldrich, St Louis, MO, USA) to digest intact nucleic acids at 37 ◦C for 30 min. Samples were
centrifuged at 6200× g for 10 min at 10 ◦C to pellet the debris.
Exosomal proteins were precipitated with an equal volume of 50% trichloroacetic acid (TCA) at
−20 ◦C overnight. The precipitated proteins were pelleted by centrifugation, washed with ice-cold
acetone, and dried at room temperature. Proteins were resuspended in 0.5 mL of solubilization
solution (7 M urea, 20 mM Tris-Cl, pH 8.0, 5 mM EDTA, 5 mM MgCl2, 4% CHAPS, 1 mM PMSF) and
quantitated using the 2-D Quant Kit (GE Healthcare Life Sciences, Pittsburgh, PA, USA). An aliquot of
0.1 mg of protein was precipitated again with 50% TCA at −20 ◦C, followed by centrifugation and a
wash with ice-cold acetone. Samples were resuspended in 0.1 mL of 100 mM ammonium bicarbonate
and 5% acetonitrile, reduced with 5 mM dithiothreitol for 10 min at 65 ◦C, alkylated with 10 mM
iodoacetamide for 30 min at 30 ◦C, and finally digested with 2 µg of sequencing grade trypsin at 37 ◦C
for 16 h. Peptides were desalted using a peptide macrotrap (Michrom Bioresources, Inc., Auburn, AL,
USA), dried at room temperature, and stored at −80 ◦C until further processing.
Desalted peptides were vacuum centrifuged until dry and resuspended in 2 µL of 2% acetonitrile,
0.1% formic acid and transferred to low retention vials in preparation for analysis using one
dimensional LC–MS/MS. Samples were transferred to low retention HPLC vials for analysis using
mass spectrometry. Peptide mass spectrometry was performed upon separation of proteins using a
one-dimensional Dionex U3000 splitless nanoflow HPLC system operated at 333 nL per minute using
a gradient from 2 to 50% acetonitrile over 4 h. The C18 column, an in-house prepared 75 µm × 10 cm
reverse phase column packed with Halo 2.7 µm, 90 A◦ C18 material (MAC-MOD Analytical), was
located in the ion source just before a Proxeon ES562 40 mm, 30 µm id stainless steel emitter. U3000
eluate was analyzed with an LTQ Velos (Thermo Scientific, Waltham, MA, USA) linear ion trap
mass spectrometer.
Scan parameters for the LTQ Velos Pro were one MS scan followed by 10 MS/MS scans of the
5 most intense peaks. MS/MS scans were performed in pairs, a CID fragmentation scan followed
a HCD fragmentation scan. All scans were performed in enhanced resolution mode. Dynamic
exclusion was enabled with a mass exclusion time of 3 min and a repeat count of 1 within 30 s of initial
m/z measurement.
2.6.2. Protein Identification
Mass spectra and tandem mass spectra were used to search subsets of the non-redundant protein
database (nrpd) downloaded from the National Center for Biotechnology Institute (NCBI; 06/14/16)
using TurboSEQUEST (Bioworks Browser 3.2; ThermoElectron, West Palm Beach, FL, USA). Analysis
was performed on avian NRPD (AVIAN DB; search terms: chicken, Gallus, Cornix, Aves, turkey, and
ostrich; NOT plant, yeast, bacteria, virus) [30].
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In addition, a non-avian vertebrate subset of the NRPD (NAVDB; search terms: mammal,
Homo sapiens, Rattus, Mus, fish, and excluding the terms used to create the AVIAN DB) was used to
identify more proteins. Trypsin digestion was applied in silico to AVIAN DB and NAVDB along with
fixed (cysteine carbamido-methylation) and variable (methionine oxidation) modifications. The peptide
MS precursor ion mass tolerance was set to 1.5 Da and the fragment ion (MS2) mass tolerance was set to
1.0 Da. Peptide matches were considered genuine if they were greater than 6 amino acids and consistent
with described X correlation and ∆Cn values. Mass spectral counts were normalized to reduce the
sample depth between samples and a likelihood ratio test was performed across leghorn VEX, leghorn
TEX and broiler TEX samples to identify significantly different patterns of expression between samples.
Proteins with an FDR-adjusted p-value (q value) of less than 0.05 were considered significant.
Refseq IDs of resulting proteins were mapped against corresponding UniprotKB IDs and
unmapped proteins were mapped against UniProt archive (UniParc) to obtain the closest hit. Protein
set enrichment analysis was performed to identify proteins previously found in EVs and deposited
in the Vesiclepedia database of vesicular proteins (v4.1, 15 Aug 2018) [31]. Functional enrichment of
cellular compartment terms was performed using Funrich_V3 [31] .
3. Results
3.1. Characterization of Exosomes Isolated from Chicken Sera
To compare exosome cargo from the vaccinated and protected, and the challenged and
tumor-bearing chickens, serum exosomes were purified from chickens in consecutive vaccine trials
(Figure 1A,B). In trial 1, the incidence of MD was somewhat lower in unvaccinated contacts compared
to the inoculated shedders, as this trial employed HyLine W36 chickens, which have been bred for
MD resistance. In trial 2, however, commercial broiler chickens were used (Ross Yield Plus males X
Ross 708 females), which show a more characteristic pattern of MD, in that unvaccinated contacts
show an increased susceptibility to MD compared to inoculated shedders (Figure 1B). In Trial 2, which
was examining HVT-based vaccines, we used only those chickens having tumors, as we did not have
significant protection with these vaccines. Neck-tags for the treatments used in our exosome isolation
and characterization are given in Table 1.
To ensure that the particles isolated from serum conformed to exosome size and morphology,
we performed nanoparticle tracking analysis of size distribution and concentration of representative
samples of serum exosomes (Figure 1C). Particles were 30–150 nm and conformed to the exosome size
range with mean sizes of 121, 122.6 and 95.8 nm for VEX, leghorn TEX, and broiler TEX, respectively
(Figure 1C). The number of exosomes per 200 µL serum were 6–8 × 108 particles per mL.
To characterize particle morphology, we evaluated the ultrastructure of both leghorn VEX and TEX
fractions via negative staining and transmission electron microscopy (TEM) Figure 1D. Our analyses
indicated the presence of variable numbers of round and irregularly-shaped vesicles of approximately
50–70 nm in size that displayed exosome morphology (Figure 1D). These vesicles were occasionally
observed as dense aggregates and were consistent with our previous observations [22].
3.2. Small RNAs Contained within Particles Conform to Exosomal Cargo
We characterized the relative size distribution of RNAs purified from the exosomal particles
via bioanalyzer (Figure 2). The RNA yields, size distribution, and profiles were typical of exosome
samples, with yields ranging from 0.29–2.27 µg and RNA sizes primarily in the 22–28 nucleotides (nts)
range (Figure 2A–C). Additionally, no ribosomal RNAs were evident (Figure 2D).
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(112,358,872, 53.2%) passed the quality filters for the presence of 3′ adaptor and insert size of 15–32 
nts after adaptor removal (Figure 3A, Table 1). In 10 of 12 libraries, at least 50% of raw reads 
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Results of the deep-sequencing of a total of 12 libraries, composed of quadruplicates leghorn
VEX, TEX and broiler TEX samples, are shown in Figure 3 and Table 1. Briefly, we obtained a total
of 211,370,657 raw single-end reads with averages of 15.9 million (VEX), 18.6 million (leghorn TEX),
and 18.3 million (broiler TEX) reads per treatment group (Table 1). Among the raw reads, about half
(112,358,872, 53.2%) passed the quality filters for the presence of 3′ adaptor and insert size of 15–32 nts
after adaptor removal (Figure 3A, Table 1). In 10 of 12 libraries, at least 50% of raw reads constituted
mappable reads. The peak length distribution of the majority of mappable reads was 21 nts (16%)
followed by 22 nts (15.2%) and 20 nts (13.9%), corresponding to the average size range of mature
miRNAs (Figure 3B).
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Figure 3. Read statistics of exoso al el ( ) shows a pie chart of the read s a stics of the
small RNA libra ies used for VEX and T ic analyses. Panel (B) shows the read lengths
of the small RNA transcriptome libraries.
Among mappable r ads, 27.1% (30,573 661) mapped to the Gallus g ll s domestic chicken reference
genom and 11.7% (13,155,489) mapped to G. gallus mRNA , whereas 7.9% (8,879,834) mapped
other RNAs including rRNA, tRNA, sn A, snoRNA, piwiRNA, etc., currently deposited in the
Rfam database. Finally, 485,729 (0.42%) of mappable mRNA reads mapped to the MDV (strain
RB-1B) genome.
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3.2.1. Cellular miRNAs Compose a Major Key Component of Exosomal Contents
A total of 3055 known unique G. gallus miRNAs were detected among the 12 libraries sequenced.
Among mappable reads, 30,573,661 (27.2%) reads mapped to known precursor and mature G. gallus
miRNAs whereas 409,687 (0.36%) reads mapped to known precursor and mature MDV-1 miRNAs
(Table 1 and Supplementary Table S1).
• miRNAs in Differential Abundance in Leghorn VEX versus TEX
Significant and differentially-expressed (SDE) G. gallus miRNAs, reflecting the differential
abundance of these species in serum exosomes (greater than 2-fold abundance in leghorn VEX
compared to leghorn TEX) included gga-miRs 146b, 143, 10b, 2188, 27b, 99a, 26a, 146c, 24, 146a
and 23b (Figure 4, Table 2). Among these, miRNAs, gga-miRs, 146a/b/c share seed sequence but
are encoded on different chromosomes (chr 13, 6, and 4, respectively) and were predicted by miRDB
algorithm to have common targets [32,33]. On the other hand, gga-miRs, 23b, 27b and 24 are part of a
common gene cluster located on the Z chromosome. G. gallus miRNAs, miR-30e and -199 were found
to be present at nearly equivalent levels in leghorn VEX and TEX, and thus, can serve as reference
controls for qRT-PCR normalization (Figure 4, Table 2).
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Table 2. Gallus miRNA read counts and miRNA abundance in leghorn VEX and TEX. 
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Figure 4. Exosomal cellular miRNAs of different abundance in VEX and TEX. The bar graph above
shows a comparison of the Log2 (PVL/TBL) of miRNA mean read number, where PVL are VEX from
vaccinated and protected leghorns, and TBL are TEX from inoculated shedder leghorns. Those to the
left are significantly over-represented in VEX, those to the right are significantly over-represented in
TEX (p < 0.01).
Finally, miRNAs with less than 2-fold abundance difference in leghorn VEX compared to leghorn
TEX or conversely, greater than 2-fold abundance in leghorn TEX compared to leghorn VEX include
gga-miRs-142, -125b, -181a, let-7i, -363, -92, -101, let-7g, gga-miRs-451, -148a, -21, -7, -15c, -16, and -16c
(Figure 4, Table 2).
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Table 2. Gallus miRNA read counts and miRNA abundance in leghorn VEX and TEX.
G. gallus miRNA p-Value Log2(VEX/TEX) Leghorn TEX Leghorn VEX
gga-miR-146b-5p 7.21 × 10−5 5.06 2046 68,424
PC-3p-53 200112 1.35 × 10−3 5.01 1134 36,566
gga-miR-10b-5p 2.03 × 10−3 4.38 21,594 449,498
gga-miR-2188-5p 3.24 × 10−2 3.65 16,457 207,103
gga-miR-27b-3p 3.24 × 10−4 3.63 8156 100,917
gga-miR-99a-5p 4.96 × 10−2 2.46 200,908 1,105,652
gga-miR-26a-5p 4.67 × 10−3 2.17 10,858 48,877
gga-miR-146c-5p 1.49 × 10−3 1.89 142,564 526,725
gga-miR-24-3p 7.26 × 10−2 1.43 3313 8949
gga-miR-146a-5p 3.91 × 10−2 1.16 18,000 40,291
gga-miR-23b-3p 6.65 × 10−2 1.16 3365 7535
gga-miR-30e-5p 4.99 × 10−2 0.88 4247 7789
gga-miR-199-3p 4.71 × 10−2 0.66 12,166 19,208
gga-miR-142-5p 3.59 × 10−2 −1.16 11,024 4947
gga-miR-125b-5p 4.55 × 10−2 −1.32 116,830 46,809
gga-miR-181a-5p 5.70 × 10−2 −1.44 31,255 11,509
gga-let-7 1.28 × 10−2 −1.83 20,148 5681
gga-miR-363-3p 2.27 × 10−2 −1.89 37,382 10,120
gga-miR-92-3p 4.55 × 10−3 −2.17 60,566 13,491
gga-miR-101-3p 3.40 × 10−3 −2.23 9426 2013
gga-let-7g-5p 6.86 × 10−4 −2.24 11,384 2417
gga-miR-451 2.47 × 10−3 −2.33 588,775 117,350
gga-miR-148a-3p 6.94 × 10−3 −2.44 113,250 20,858
gga-miR-21-5p 4.20 × 10−3 −2.88 120,353 16,302
gga-miR-7 1.86 × 10−3 −3.21 47,490 5122
gga-miR-15c-5p 1.50 × 10−2 −3.39 5628 537
gga-miR-16-5p 4.77 × 10−4 −3.45 10,178 934
gga-miR-16c-5p 7.74 × 10−5 −4.03 20,103 1231
Among these, miR-92 and -363 share seed sequence and belong to paralog clusters miR-17-92
(located on chr 1) and miR-106a-363 (located on chr 4), respectively. In addition, let-7 family miRNAs,
let-7i and let-7g also share seed sequence and are located on chr 1 and 15, respectively. Furthermore,
miR-15c, -15 and -16c, also share seed sequence and belong to the miR-15-16 family of miRNAs.
The miR-15-16 miRNA family exists in 4 paralog clusters in vertebrates, where the miR-15a/16-1
cluster flanks the TRIM13 gene on chr4, and miR-15c-16c cluster flanks the HPRT gene on chr1, with
both clusters sharing a common 7 nt seed sequence.
• miRNAs in Differential Abundance between VEX and Broiler TEX
SDE G. gallus miRNAs that were at greater than 2-fold abundance in leghorn VEX compared to
broiler TEX included gga-miRs 99a, 2188, 10b, 1388, let-7f, 146b, 26a, 27b, 30e, 146c, and 23b (Table 3).
As indicated above, miR-27b and -23b originate from 23b~27b~24-1 cluster and miR-24 was found to
be expressed at relatively equivalent levels in both leghorn VEX and broiler TEX. Finally, miRNAs
that were less in abundance than 2-fold in leghorn VEX compared to broiler TEX or conversely, those
displaying greater than 2-fold expression in broiler TEX include gga-miRs, 199, 425, 181a, 92, let7i,
181a, 126, 148a, 363, 21, 122, 142, 199 and 140 (Table 3).
Those miRNAs expressed in greater abundance in leghorn VEX compared to either source of TEX,
were cellular gga-miRs-99a, -2188, -10b, -146b, -26a, -27b, -146c, and -23b. Similarly, miRNAs greater in
abundance in either source of TEX compared to VEX include gga-miRs-92, -363, -148a, -181a, and -21,
suggesting that these are truly tumor-associated miRs.
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Table 3. Gallus miRNA read counts and miRNA expression in VEX and broiler TEX.
G. gallus miRNA p-Value Log2(VEX/TEX) Broiler TEX Leghorn VEX
gga-miR-99a-5p 1.08 × 10−2 3.58 92,713 1,105,652
gga-miR-2188-5p 3.56 × 10−2 3.52 18,115 207,103
gga-miR-10b-5p 1.73 × 10−2 2.89 60,577 449,498
tgu-miR-1388-5p 1.20 × 10−2 1.81 14,403 50,359
gga-let-7f-5p 8.60 × 10−3 1.70 4454 14,519
gga-miR-146b-5p 1.58 × 10−2 1.70 21,014 68,424
gga-miR-26a-5p 2.81 × 10−2 1.53 16,930 48,877
gga-miR-27b-3p 1.99 × 10−2 1.49 35,868 100,917
gga-miR-30e-5p 3.23 × 10−2 1.41 13,857 36,839
gga-miR-146c-5p 8.41 × 10−3 1.34 208,239 526,725
gga-miR-23b-3p 6.49 × 10−2 1.06 3625 7535
gga-miR-30e-5p 8.75 × 10−2 0.82 4423 7789
gga-miR-24-3p 4.70 × 10−2 0.72 5445 8949
gga-miR-199-3p 8.75 × 10−2 −0.53 27,729 19,208
tgu-miR-425-5p 3.19 × 10−2 −0.78 5509 3198
gga-miR-92-3p 9.08 × 10−2 −0.85 24,402 13,491
gga-let-7i 2.78 × 10−2 −0.86 10,306 5,681
gga-miR-181a-5p 3.78 × 10−2 −0.88 21,235 11,509
gga-miR-126-3p 7.58 × 10−2 −1.05 10,493 5052
gga-miR-148a-3p 4.52 × 10−2 −1.15 46,178 20,858
tgu-miR-363-3p 6.53 × 10−3 −1.31 25,070 10,120
gga-miR-21-5p 4.23 × 10−3 −1.35 41,470 16,302
gga-miR-122-5p 2.98 × 10−2 −1.56 13,321 4527
gga-miR-142-5p 4.89 × 10−3 −2.08 20,957 4947
gga-miR-199-5p 1.00 × 10−2 −2.18 77,490 17,139
gga-miR-140-3p 1.07 × 10−4 −2.19 10,748 2359
3.2.2. MDV-Encoded miRNAs Differ in Abundance between VEX versus TEX
To assess the relative expression of MDV-encoded miRNAs in VEX versus TEX, we examined the
relative abundance of the different viral miRNAs species by individual bird numbers and treatments
(Figure 5, Supplementary Tables S1–S3). All MDV miRNAs belonging to the Marek’s disease virus
EcoRI-Q-fragment-encoded gene (meq)and LAT clusters were detected in VEX and TEX except for
miR–M31 (Meq cluster 2), which was identified consistently in broiler TEX and in two samples of
leghorn TEX, but not in any VEX samples (Figure 5, Supplementary Tables S1–S3).
In terms of MDV-encoded miRNAs, we observed the following patterns of expression: (a) the
cluster of miRNAs upstream of meq were expressed consistently higher in TEX compared to VEX, in
particular M4 was present 1–2 orders of magnitude higher in TEX compared VEX (Figure 5, Table 4),
(b) the cluster of miRNAs downstream of meq were present at lower levels in VEX, and their abundance
in TEX was lower than the meq upstream cluster (Figure 5C, Table 4), and (c) the LAT cluster of
MDV-encoded miRNAs were intermediate in abundance between the meq upstream and downstream
clusters (Figure 5D, Table 4).
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Table 4. Expression levels of MDV-encoded miRNAs in TEX compared to VEX.
L ghorn TEX/Leghorn VEX Broiler TEX/Leghorn VEX
miRNA Origin
Cluster MDV-1-miR- Fold Change p-Value
Fold
Change p-Value
meq cluster 1
-M9 9.41 0.22 39.43 0.07
-M5 1.47 0.60 15.49 0.02
-M12 3.44 0.37 49.00 0.08
-M3 13.04 0.26 43.70 0.07
-M2 2.19 0.39 40.60 0.03
-M4 10.36 0.33 28.99 0.03
meq cluster 2
-M11 4.27 0.16 69.20 0.01
-M31 0.00 0.19 - -
-M1 1.20 0.89 19.10 0.04
LAT cluster
-M8 3.85 0.02 13.83 0.08
-M13 4.33 0.32 10.78 0.05
-M6 7.63 0.28 41.15 0.04
-M7 22.45 0.16 37.38 0.01
-M10 2.18 0.36 27.65 0.06
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3.2.3. Target Pathways Predicted to Be Affected by VEX and TEX Cellular miRNAs
As we hypothesized that VEX- and TEX-borne miRNAs would target different pathways, we
examined the predicted G. gallus gene targets for these miRNAs and the number of targets ranged
from 6 to 987 for total predictions, and from 8 to 355 for predictions having a gene score ≥80 (Tables S4
and S5, Supplementary file S3). To explore the biological processes associated with VEX-upregulated
miRNAs, a complete set of miRNA gene targets was used for gene enrichment analysis via DAVID
gene ontology (GO) tool [27]. By this analysis, lists of 715 and 901 gene targets were identified for
VEX-upregulated miRNAs compared to leghorn and broiler TEX, respectively (Supplementary files S1,
S3). DAVID successfully mapped 690 of 715 and 864 of 901 gene symbols to G. gallus genes.
KEGG pathway analysis predicted 6 pathways likely to be affected by VEX-borne miRNAs,
and 13 and 10 pathways likely to be affected by leghorn and broiler TEX miRNAs, respectively
(Supplementary files S1, S3). The pathway predicted to be most significantly affected by VEX was the
mitogen-associated protein kinase (MAP kinase) pathways (MEK/ERK, p38 and JNK) (Supplementary
Figure S1A). This was the only pathway to have a false-discovery rate (FDR) <0.05.
In terms of pathways most likely to be affected by both leghorn and broiler TEX, the
phosphatidylinositol signaling pathway had false-discovery rates (FDR) ≤0.05 for both sets of TEX
(Supplementary Figure S1B). Among the enriched pathways, the top 8 pathways predicted to be
affected were the same between TEX isolated from layers and broilers, albeit not in the same order
(Supplementary files S1, S3). Of the pathways predicted to be affected by TEX, five were also predicted
to be targeted by VEX, as well, although different members of the pathways were the predicted targets
(Supplementary files S1, S3).
3.2.4. VEX and TEX Contain MDV mRNAs
In addition to miRNAs mapping to the genome, we identified mRNAs which also mapped to the
MDV genome (pRB-1B reference strain) (Figure 6). The number of reads that mapped to reference sequence
to produce a contig were 86,000 (leghorn VEX), 122,113 (leghorn TEX) and 265,616 (broiler TEX) (Table 1).
Since the unique mappable reads obtained in our current study were the result of size selection prior to
small RNA sequencing, and were further subjected to quality control steps to ensure read lengths between
15–32 nts, reads mapped to the reference genome may be the result of sequencing of fragmented
exosomal transcripts or incomplete reverse transcription products during sample preparation.
The number of raw reads accounted for mapping to the coding regions of MDV genome were
133,627 (leghorn VEX), 1242 (leghorn TEX), and 1044 (broiler TEX) (Supplementary file S2). A total of
140 genes (minimum of 5 reads/transcript) were identified in sample libraries corresponding to leghorn
VEX, whereas only 6 and 16 genes had at least 5 reads mapped in sample libraries corresponding to
leghorn TEX and broiler TEX, respectively (Figure 6, Supplementary file S2). The lack of raw read counts
and normalized expression values for a major proportion of MDV genes in leghorn or broiler TEX
precluded us to evaluate differential gene expression between leghorn VEX and leghorn or broiler TEX.
Upon normalizing raw read counts, gene expression values indicated the top 20 genes of highest
expression in their descending order of expression including UL34 (nuclear envelopment in complex with
UL31), RLORF12, UL35, UL42 (viral DNA polymerase processivity factor), UL20, RLORF7 (Meq), UL33
(minor capsid protein), MDV103, LORF9, UL40 (ribonucleotide reductase), UL29 (single-stranded DNA
binding protein), UL9 (origin binding protein), UL32 (procapsid chaperone and viral oxidoreductase),
L1, UL46 (VP11/12 tegument protein), US6 (glycoprotein D), UL19 (major capsid protein), UL24,
RLORF13 (pp38) and UL23 (viral thymidine kinase) (Figure 6, Supplementary file S2) [34,35].
Among these were genes that have essential functions in herpesviral genome replication (UL9,
UL42, U29, UL40, UL23), capsid assembly (UL33, UL35, UL19), DNA encapsidation (UL32), nuclear
egress (UL34), cytoplasmic capsid maturation, and egress (VP11/12, US6, UL24, UL20) [24,29,35,36].
In addition to these, normalized abundance analysis indicated gene expression from a majority
of MDV genome in VEX, including gene segments from both unique and repeat regions (Figure 6,
Supplementary file S2).
Genes 2019, 10, 116 17 of 30
Genes 2019, 10, 116 17 of 32 
 
 
Figure 6. Exosomal mRNAs mapping the MDV genome. Panel (A) shows the raw read number of 
exosomal mRNAs mapping to the MDV genome from leghorn VEX (blue), leghorn TEX (green) and 
broiler TEX (red). Panel (B) shows these data normalized to gene size and read abundance (RPKM). 
Note localization differences between VEX (numerous MDV structural, enzymatic and regulatory 
genes), and TEX (primarily latency/transformation-associated genes). For reference, common gene 
names and maps of the MDV genome are included along and below the X-axis, respectively, in each panel. 
The number of raw reads accounted for mapping to the coding regions of MDV genome were 
133,627 (leghorn VEX), 1242 (leghorn TEX), and 1044 (broiler TEX) (Supplementary file S2). A total of 
140 genes (minimum of 5 reads/transcript) were identified in sample libraries corresponding to 
leghorn VEX, whereas only 6 and 16 genes had at least 5 reads mapped in sample libraries 
corresponding to leghorn TEX and broiler TEX, respectively (Figure 6, Supplementary file S2). The 
lack of raw read counts and normalized expression values for a major proportion of MDV genes in 
leghorn or broiler TEX precluded us to evaluate differential gene expression between leghorn VEX 
and leghorn or broiler TEX. 
Upon normalizing raw read counts, gene expression values indicated the top 20 genes of highest 
expression in their descending order of expression including UL34 (nuclear envelopment in complex with 
UL31), RLORF12, UL35, UL42 (viral DNA polymerase processivity factor), UL20, RLORF7 (Meq), UL33 
(minor capsid protein), MDV103, LORF9, UL40 (ribonucleotide reductase), UL29 (single-stranded DNA 
binding protein), UL9 (origin binding protein), UL32 (procapsid chaperone and viral oxidoreductase), L1, 
UL46 (VP11/12 tegument protein), US6 (glycoprotein D), UL19 (major capsid protein), UL24, RLORF13 
(pp38) and UL23 (viral thymidine kinase) (Figure 6, Supplementary file S2) [34,35]. 
Among these were genes that have essential functions in herpesviral genome replication (UL9, 
UL42, U29, UL40, UL23), capsid assembly (UL33, UL35, UL19), DNA encapsidation (UL32), nuclear 
egress (UL34), cytoplasmic capsid maturation, and egress (VP11/12, US6, UL24, UL20) [24,29,35,36]. 
Figure 6. Exosomal mRNAs mappi t e V genome. Panel (A) shows the raw read number of
exosomal mRNAs mapping to the DV genome from leghorn VEX (blue), leghorn TEX (green) and
broiler TEX (red). Panel (B) shows these data normalized to gene size and read abundance (RPKM).
Note localization differences between VEX (numerous MDV structural, enzymatic and regulatory genes),
and TEX (primarily latency/transformation-associated genes). For reference, common gene names and
maps of the MDV genome are included along and below the X-axis, respectively, in each panel.
In contrast to VEX, normalized read abundance in leghorn TEX mapped to only [4] genes including
RLORF8, L1, ICP4, and UL30 in descending order of expression. Other gene products not described
here, had read counts were less than 5 (Figure 6, Suppl mentary file S2). The remaining MDV gene
products lacked any xpression in legh rn .
In broiler TEX, read corresponding to a total of 14 MDV genes were identified as having read
numbers >5 including RLORF8, L1, UL3, UL34, LORF3, RLORF1 (viral telomerase RNA or vTR),
UL12, UL46 (VP11/12), UL32, ICP4, UL8 (DNA helicase/primase complex associated protein), UL17
(tegument protein), and UL36 major tegument protein (MTP) (Figure 6, Supplementary file S2).
Of note, the MDV meq cluster 1 miRNAs, miR–M4, and –M2, whose read counts accounted for
66.73% and 1.76% of total number of miRNA reads, respectively, in leghorn TEX, and 36.35% and 6.36%
of total number of miRNA reads in broiler TEX, respectively, fall within the RLORF8 coding region
(Supplementary Table S2). Thus, the greater expression of MDV-miR-M4 in leghorn or broiler TEX
may account for the highest expr ssion of RLORF8 as precursor RNAs. In general, leghorn and broiler
TEX mRNAs mapping to the MDV genome were in much lower abundance than those contained in
VEX (Figure 6, Supplementary file S2), with the exception of those mapping to the repeats flanking the
unique long region (IRL/TRL).
3.3. Determining Protein Biomarkers of VEX and TEX
To assess differential protein content between VEX and TEX, an average 358 ± 48 proteins (mean
of 1386 ± 86 peptides) for VEX, an average of 461 ± 80 proteins were identified (mean of 1643 ± 354
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peptides) for leghorn TEX, and 420 ± 30 proteins (mean of 1739 ± 129 peptides) were identified from
broiler TEX (Supplementary files S4, S5). Of these, 69 proteins were common to all three exosome
preparations, and 221 and 208 proteins were unique to leghorn and broiler TEX, respectively, suggesting
that cellular transformation by MDV significantly altered exosome content (Figure 7). Of the identified
proteins, 213/317 (67%), 309/482 (64%), and 292/433 (67%) were successfully mapped by Funrich
functional enrichment tool among which, 193, 282, and 258 proteins were present in the Exocarta
database of previously reported exosome proteomes (Figure 7B, Supplementary files S6–S8).
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Figure 7. Proteomic analysis of leghorn VEX, TEX and broiler TEX. Pane (A) shows a Venn diagram of
proteins identified in leghorn VEX, leghorn TEX and broiler TEX. Panel (B) shows a Venn diagram of
datasets compared to the Vesiclepedia database of proteins [37], see also Supplementary files S5–S7).
Panel (C) shows the Funrich enrichment of subcellular localization of proteins identified in leghorn
VEX, TEX and broiler TEX.
The unmapped prote ns lso ncluded previously identified xosomal p ote ns, for instance,
histone subunits (H2A, H2B), integrin subu its (ITGB), acti subunits (ACTA3, ACTSG, ACT5,
ACTC), tubulin chains (TBA2, TBA3, TBA4A, TBB2, TBB4, TBB5, TBB6), cytochrome subunit
(CYTB), alpha-2-microglobulin –like 4 (A2ML4), cytokine receptor chain subunits (IL10R1, gp130)
and MDV proteins, which remained unrecognized by Funrich tool due to variations between
G. gallus nomenclature and respective orthologs belonging to H. sapiens, which is used by Funrich
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(Supplementary files S6–S8). These data further suggest that the vesicle preparations in our study
contained abundant levels of exosomes.
The proteomic analysis also identified 71 novel exosome proteins not present in Exocarta, as indicated
in the Venn diagram (Figure 7B). As anticipated with the latent and tumorigenic phase of MDV infection,
there was a significant alteration in exosome content, of which 45 proteins common to both leghorn and
broiler TEX were not identified in leghorn VEX (Figure 7B, Supplementary files S6–S8).
By convention, exosome characterization relies on the detection of common marker proteins enriched
in exosome fractions. These include tetraspanins (CD9, CD63, CD81), exosome biogenesis proteins (Tsg101,
Alix), and others (Syntenin-1, Flotillin-1) [38]. However, none of these except tetraspanin-10 were detected
in our exosome samples. Nonetheless, exosomal proteins previously reported to be associated with vesicle
secretion in cancer cell line supernatants (RAP1A, RAP1B, VAMP1, MYH7, MYO18a, MYOLPF, MYO1E,
VPS13B, HSP70) were identified in our samples [38]. Furthermore, comparison to the Vesiclepedia
database revealed 32.8–41.5% of the proteins identified in our datasets were predicted to be exosomal,
and the majority were localized to endolysosomal compartments (Figure 7C).
Exosomal protein functional groups in leghorn VEX include membrane receptors (C1r, EphA4),
metabolic enzymes (GAPDH, LCAT, PCY1OXL), heat shock proteins (HSPA9), cytoskeletal proteins
(ActA, ActB, ActG1, myo1E, tub2, -4, -5, -7), histones (H2A-I, -II, -IV, VI, H2B), ribosomal proteins
(mRPS31), vesicle trafficking proteins (VAMP1, STXBP4, ArfGef12). The only MDV-encoded proteins
identified in low abundance were immediate early protein, ICP4 in VEX, and UL36 (major tegument
protein), UL47 (tegument protein) in TEX of both origins (leghorn and broiler) (Supplementary files S4, S5).
Among overrepresented proteins identified in leghorn VEX in comparison to both TEX samples
include collagen α-1, XXII chain (COL22A1), and IGFBP-complex acid labile subunit isoform
(IGFBPALS) (Supplementary Table S5). COL22A1 is associated with tissue integrity, myotendinous
junctions, and cellular adhesion. IGFBPALS, aka IGFBP-5, is similarly associated with systemic tissue
integrity, and has been previously demonstrated to be expressed in exosomes [38].
Common functional groups of exosomal proteins identified in leghorn TEX included β2m,
membrane receptors (THRB, TSPAN10, C1r), metabolic enzymes (PKM, ENO1, GAPDH, LCAT),
elongation factors (Eef1a2, Eef1B2, Eef2, Eif2s3, eIF4A2), heat shock proteins (HSPA4L, Hspbp1),
cytoskeletal proteins (ActA, ActB, ActG2, myl6, my015a, tubb, tuba, DNAH), histone subunits (H3-I, -II,
-III, -IV, -V, -VI, -IX, H4-I, -II, -III, -IV, -V, -VI, H2A-VII, H2A-VI, H2A-VIII), ribosomal proteins (RPL-4,
-5,-6,-10a,-17, -P1, -P2, RPS-2, -6, -19), vesicle trafficking proteins (VPS13A), chromatin modifying enzymes
(KAT5, NSD1, H3K36me, H4K20me, ATM) and pro-apoptotic protein (BID) (Supplementary Table S5).
Common functional groups of exosomal proteins identified in broiler TEX includeβ2m, membrane
proteins (CD36, CD48, CD5L, CD163L1), membrane receptors (INSR, CFTR, DMBT1), metabolic
enzymes (PKM, ENO1, GAPDH, LCAT, PCYOX1L), elongation factors (Eef1a2, Eef2S3), heat shock
proteins (Hsp5), cytoskeletal proteins (ActA1, ActB, ActA2, ActBl2, ActG1, myh6, myh7, tubb, tuba),
histone subunits (H2B-I, H2B-II, H2B-III, H2B-IV, H2B-VI, H2A-VII, H2A-VI, H2A-VIII), ribosomal
proteins (RPL-4, -5, -6, -10a, -17, -P1, P2, RPS-2, -6, -19), vesicle trafficking proteins (RanBP), and
transcription factors (JunD, E2F4, YEATS2) (Supplementary Table S6).
3.3.1. Enrichment Analysis of Exosomal Transcription Factors (TFs)
The presence of viral and cellular transcription factors (TF) in leghorn VEX or TEX (leghorn and
broiler) permitted gene enrichment analysis based on transcription factors and associated targets in
proteomic datasets (Figure S2). The top 6 transcription factor networks enriched in each treatment
group were identified. While Bonferroni-corrected TF networks pertaining to HNF1A and ARID3A
remained common to leghorn VEX and leghorn and/or broiler TEX, respectively, TF networks FOXA1,
RXR, RREB1 and YY1 remained unique to leghorn VEX (Figure S2A, Supplementary files S7–S9).
Similarly, Bonferroni-corrected TF networks associated with Jun, FosB and NKX6.1 remained common
to leghorn and broiler TEX (Figure S2B,C). The only TF network unique to leghorn TEX was MEF2A,
whereas those networks uniquely-identified to broiler TEX include ONECUT1 and Fos (Figure S2C).
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3.3.2. Putative Protein Biomarkers of VEX and TEX
Comparison of proteins consistently-identified in VEX or TEX (leghorn or broiler) identified
several proteins that were indicative biomarkers of VEX or TEX (Table 5; Table 6, Supplementary
files S4, S5). In VEX of leghorn chickens, collagen α1 XXII (COL22A1) was identified as significantly
more abundant compared to TEX of layers (>10,000-fold, p < 0.05), and broilers (>25-fold, p < 0.05)
(Table 5). Similarly, insulin-like growth factor, acid-labile subunit (IGFALS) was more abundant in
VEX than in TEX of leghorns (>1000-fold, p < 0.02), and broilers (>850-fold, p < 0.05). Consequently,
each of these may serve as exosomal biomarkers for assessing vaccine-induced protection from MD.
There were additional proteins identified consistently-associated with protection (protocadherin-17,
IgGFc-binding protein-like protein, tenascin receptor, Muellerian-inhibiting factor, transferrin receptor,
and the C-reactive protein, pentraxin-related precursor, etc., (see Table 5); however, these differences in
detection were statistically significant in one comparison (i.e., leghorn VEX vs. TEX) but not the other
(Supplementary files S4, S5).
Table 5. Serum VEX-overrepresented proteins.
Protein Name (Accession#) VEX (NI) 1 TEX (NI) 1 RatioVEX/TEX p-Value
Protocadherin-17 (XP_015132312.1) 2.31 0 11,109:1 0.015
Collagen -1 (XXII) chain (XP_015138660.1) 1.13 0 10,825:1 0.048
IgGFc-binding protein-like protein (XP_428412.5) 0.6 0 2851:1 0.035
Insulin-like growth factor-binding protein complex acid labile
subunit isoform (XP_425222.3) 0.24 0 1159:1 0.014
Tenascin isoforms (XP_015134827.1) 0.15 0 998:1 0.014
Insulin-like growth factor-binding protein complex acid labile
subunit isoform (XP_425222.3) 0.24 0 851:1 0.043
Muellerian-inhibiting factor precursor (NP_990361.1) 0.21 0 733:1 0.043
Collagen -1 (XXII) chain (XP_015138660.1) 1.13 0.04 27:1 0.039
Transferrin Receptor (XP_015146868.1) 0.1 0.01 12:1 0.005
C-reactive protein, pentraxin-related precursor (NP_001300649.1) 2.13 0.43 4.9:1 0.014
1—normalized intensity; Leghorn VEX/TEX (top 5 Leghorn VEX/Broiler TEX (bottom 5).
In terms of TEX-associated marker proteins, isoforms of pantetheinase (aka, vanin-1) were
consistently identified in TEX, but not in VEX (leghorn TEX > 12,000-fold, p < 0.01; broiler TEX
> 6500-fold, p < 0.02), see Table 6. Additional markers included histone H4, α-2-antiplasmin isoform X2,
HSP90-α, peroxiredoxin-1, deleted in malignant brain tumors-1 protein-like isoform X2, ceruloplasmin,
clusterin, and mannose-binding lectin precursor, etc.; however, these were only statistically significant
in one comparison (e.g., leghorn TEX vs. VEX), but not the other (Supplementary files S4, S5).
Table 6. Serum TEX-overrepresented proteins.
Protein Name (Accession#) VEX (NI) 1 TEX (NI) 1 Ratio TEX/VEX p-Value
Histone H4 (XP_425458.2) 0 9.94 44,448:1 0.015
-2-antiplasmin isoform X2 (XP_015151528.1) 0 4.36 19,487:1 0.014
HSP90-α (NP_001034377.1) 0 3.12 13,971:1 0.029
Pantetheinase isoform X1 (XP_015139593.1) 0 2.77 12,388:1 0.005
Peroxiredoxin-1
(NP_001258861.1) 0 2.46 11,102:1 0.043
Deleted in malignant brain tumors 1 protein-like isoform X2
(DMBTL) (XP_015156078.1) 0 11.8 52,741:1 0.048
Ceruloplasmin (XP_015147339.1) 0 1.85 8265:1 0.014
Pantetheinase isoform X3 (XP_015139595.1) 0 1.51 6734:1 0.013
Clusterin precursor (NP_990231.1) 0 1.3 5815:1 0.013
Mannose-binding lectin precursor (NP_989680.2) 0 1.23 5515:1 0.01
1—normalized intensity; Leghorn TEX (top 5), Broiler TEX (bottom 5).
4. Discussion
This is the first report of the complete transcriptomic and proteomic analyses of chicken serum
exosomes from commercial leghorn and broiler Marek’s disease virus vaccine studies. The cellular
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cargo miRNAs showed distinct patterns of abundance suggesting that VEX miRNAs target the MAP
kinase, cellular proliferation pathway (Figure S1A). Both sets of TEX-borne miRNAs showed significant
targeting of phosphoinositol signaling (Figure S1B), suggesting that these would disrupt pathways
essential to lymphocyte activation, and would therefore likely be immunosuppressive.
4.1. Abundant VEX-Borne miRNAs
As mentioned in the results, the most abundant miRNAs found in VEX were the miR-146 family,
the miR-23 cluster, and miR-26a, among others. These miRNAs have been associated with modulation
of innate immune responses and T-cell patterning, and are described briefly, below.
4.1.1. The miR-146 Family
MiR-146a and -146b share seed sequences, and thus have common predicted targets and differ
by two 3′-end nucleotides. These were initially identified as endotoxin-inducible miRNAs via TLR4
signaling [32,33]. miR-146a and -146b function as negative regulators of NFκB, by targeting IRAK1 and
TRAF6, resulting in decreased pro-inflammatory cytokine production. In our study, chicken IκB kinase
subunit β (IKBIP or IKKβ), was found to be a high confidence target (miRDB score: 84) of miR-146a/b,
suggesting that VEX may negatively regulate NF-κB.
4.1.2. The miR-23~27~24 Cluster
This cluster consists of 3 members existing as two paralogs (a and b) [39]. Mature miR-23a and
miR-27a differ by one nucleotide with respect to their paralogs miR-23b and miR-27b, whereas miR-24-1
and -2 share the same sequence. Although it is hypothesized that evolutionarily-conserved miRNA
clusters cooperatively target the same gene or various components of a common biological process,
members of 23~27~24 cluster have antagonistic roles rather than cooperative roles in modulating
effector T-cell differentiation [39].
Cellular miR-23b displayed anti-inflammatory properties in human cells by directly repressing
NFκB signaling activators, TGF-β activated kinase 1/MAP3K7 binding protein 2 (Tab2), Tab3, and
inhibitor of nuclear factor B kinase subunit α (IKK-α) [40]. Among the above, we identified Tab3
(miRDB score: 95) and a previously confirmed target gene chicken IRF1 (miRDB score: 91) as miR-23b
predicted targets, corroborating convergent evolution and suggesting that miR-23b may also contribute
to pro-inflammatory cytokine downregulation.
Cellular miR-24 overexpression was demonstrated to promote Th1 and Th17 differentiation of
naive T cells [39]. In addition, miR-24 can also target IL-4 expression in an indirect manner as shown
for miR-27 mediated targeting of GATA3 by targeting Bmi1, a molecule that stabilizes GATA3 by
blocking its proteasome-dependent degradation [41]. The observed greater levels of miR-27b and -24
compared to miR-23b in VEX, suggest that MD vaccination leads to maintained Th1 differentiation.
A putative tumor suppressor role for miR-27b is suggested by its deletion in a docetaxel-resistant
luminal-type human breast cancer cell line [42]. Similarly, in numerous cancers, forced-expression
induces a loss of invasiveness in numerous cancer cell lines [43,44]. In this regard, several of the
miR-27b targets: LIMK1 (miRDB score:98), CDH5 (miRDB score:97) and VEGFC (miRDB score:62)
were among predicted chicken targets of G. gallus miR-27b.
Cellular miR-24, conversely, displays a context-dependent role as a tumor suppressor or
pro-oncogenic miRNA, in that it suppressed cell proliferation and migration in prostate cancer, arterial
smooth muscle cells, vascular muscle cells, nasopharyngeal carcinoma, bladder cancer, and small-cell
lung cancer, but acts as an oncomiR in glioma, Hodgkin’s lymphoma, and SQCC [45,46]. In the context
of MD lymphomas, the relative high abundance level of miR-24 in VEX suggests that it may function
in a possible tumor suppressor role.
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4.1.3. miR-26a
Cellular miR-26a functions as a tumor suppressor miRNA in nasopharyngeal carcinoma (NPC),
breast cancer, lung cancer, and hepatocellular carcinoma (HCC), although it has also been associated
with tumor cell proliferation in glioma and CCA [42,47–49]. Additional previously-validated miR-26a
targets identified in our prediction analysis include SMAD1, MTDH, CDK6, PTEN, and MAP3K2
(Figure 6A) [50,51]. A further suggestion of the tumor suppressor role of miR-26a in the context of MD
lymphomas was the finding that miR-26a is significantly-downregulated in vMDV (GA)-infected spleen
and liver tumors compared to uninfected spleens and uninfected PBLs, respectively [52]. miR-26a was
found to be downregulated in seven independently-derived MDV-transformed lymphoblastoid cell
lines, as well as ALV-and REV-transformed lymphoblastoid cell lines [53].
4.1.4. VEX-Borne miRNA Targeted Cellular Pathways
In terms of VEX-borne miRNAs, our pathway prediction suggests that mitogen-associated protein
kinase (MAPK) signaling is targeted for downregulation at multiple targets (Figure S2).
4.2. TEX-Borne miRNAs
The most abundant miRNAs consistently found in TEX were miR-92/-363 cluster, let 7i and 7g,
and miR-21. These miRNAs, as well as MDV-encoded miRNAs, have been associated with various
malignancies, and their abundance in TEX suggest contributory roles in MDV-mediated transformation
and immune suppression.
4.2.1. miR-92 and -363
Cellular miR-92 is transcribed as part of a polycistrionic miR-17-92 cluster, a.k.a oncomiR-1, which
encodes 6 miRNAs including miR-17, -18a, -19a, -19b-1, -20a and -92a [54]. In addition to the miR-17-92
cluster, there exist two paralog clusters including the miR-106a-363 cluster (containing miR-106a, -18b,
-20b, -19b-2, -92-2 and -363), and the miR-106b-25 cluster (containing miR-106b, -93, -25) which encodes
miR-92 paralogs miR-92a-2, -363 and -25, respectively [55]. Although miR-92a-2 and miR-363 are
co-expressed as part of polycistrionic transcript, varying post-transcriptional processing results in
differential processing of these mature miRNAs [55].
In TEX, miR-92 and -363 were found to be in greater abundance compared to VEX. In addition,
with a read number less than 2000 (below the set detection limit) remaining miRNAs of the miR-17-92
cluster (miR-17, -19a, -20a), and miR-106a-363 cluster (miR-20b, -106) were also found in greater
abundance compared to VEX.
Amplification of the miR-17-92 cluster-coding region is found in cell lines representative of
several types of hemopoietic malignancies including: splenic lymphoma with villous lymphocytes, six
mantle lymphoma cell lines, ATN-1 (adult T-cell lymphoma cell line), Jurkat (T-cell acute lymphocytic
leukemia), HT-1 (T-cell lymphoblastic lymphoma cell line, HTLV-1-negative) and HUT78 (peripheral
T-cell lymphoma cell line) [56]. MiRs -19a, -20 and -92a were overexpressed in these lymphoma
cell lines, whereas miR-17a and -18 were found at lower levels. Furthermore, overexpression of the
miR-17-92 cluster in transgenic mice caused B cell lymphomas [57]. Based on greater expression
of miR-92 and -363 in TEX and their previous roles as oncomiRs, our data suggest that they may
contribute to MDV-mediated lymphomagenesis.
4.2.2. Let-7i and -7g
The cellular miRNAs let-7g and let-7i belong to the let-7 family of miRNAs, which are known
tumor suppressor miRNAs downregulated in a variety of malignancies. In contrast to their role in
many cancers, let-7i was found to be highly upregulated in follicular lymphoma tissues from patients
that underwent transformation (FCL-t). Likewise, let-7a, -7b, -7i and -7f were consistently upregulated
in Hodgkin’s lymphoma cell lines and tissues irrespective of EBV-infection status [58].
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4.2.3. miR-21
Cellular miRNA mir-21 is a bona fide oncomir that is overexpressed in virtually all carcinomas
and various hematological malignancies including MDV1-induced lymphomas, and is transactivated
by Meq [59,60]. Mir-21 targets numerous gene products including MyD88 and IRAK1 to promote
immune suppression [61].
4.2.4. MDV-Encoded miRNAs
Other TEX-borne miRNAs with potential roles in MD lymphomagenesis include the MDV miRNA
clusters. In terms of MDV-encoded miRNAs, we found that most were identified in both VEX
and TEX; however, the meq-cluster 1 (cluster upstream of meq), were the most abundant species
identified and were of ~10-fold greater abundance in TEX compared to VEX (Figure 5). MDV-encoded
miRNAs downstream of meq were in least abundance (~100-fold less than the upstream cluster), with
significant bird-to-bird variation in the abundance of the different species; however, in leghorn TEX,
this cluster was more consistently-identified than in VEX. The latency-associated transcript (LAT)
cluster of miRNAs were intermediate in expression between the meq-upstream, and -downstream
cluster miRNAs. This LAT cluster was identified in 3 to 4-fold greater abundance in TEX than in VEX.
Overall, our data support the role of the meq-upstream miRNA cluster, particularly M4, in
contributing to systemic immune suppression and likely contributing to cellular transformation [5,62,63].
4.2.5. TEX-Borne miRNA Targeted Cellular Pathways
In our studies of TEX-borne cellular and viral miRNAs, we found that the consistently-targeted
cellular genes by TEX from either source, were those involved in phosphoinositol signaling. Targeted
genes in this signaling includes class I PI3K catalytic subunits (PIK3CB/PI3Kβ, PIK3CD/PI3Kδ),
PI3K regulatory subunit (PIK3R1/p85α), downstream PI(3,4,5)P3 phosphatase (PTEN), PI3P kinase
(PIKfyve), phosphoinositide hydrolases (PLCB, PLCB1, PLCL2), diacylglycerol (DAG) kinases (DGKB,
DGKD, DGKH), inositide triphosphate (IP3) receptor (ITP1R) and inositol phosphatases (IMPA1,
IMPAD, INPP5A, SYNJ1, SYNJ2, MTMR6, MTMR12) (Figure S2, Table S5, Supplementary files S1, S3).
Class I PI3K, PI3Kδ mediates downstream signaling of growth factors, cytokines, and immune
receptors such as B-cell, T-cell, and Toll-like receptors [64]. The targeting of upstream catalytic
and regulatory subunits to prevent downstream signaling may promote TEX-mediated immune
suppression. On the other hand, PTEN balances and counteracts PI3K activity by PI(3,4,5)P3 hydrolysis,
and attenuated expression, loss of function mutations, or total loss of PTEN is indicated in many
forms of malignancies, while PIK3CA over-activation, due to mutations, is also indicated in cancer
progression [64].
4.3. VEX/TEX-Borne MDV mRNA Expression
In terms of the MDV-encoded mRNAs identified in VEX and TEX, we report a very stark,
and likely incredibly important difference in the abundance of transcripts between these exosomes.
Contrary to our initial hypothesis, in which we believed that MDV-associated mRNAs would be
primarily identified in TEX, and would map exclusively to the transformation- associated genes (meq,
RLORF4, vTR region), we found much higher levels of MDV mRNAs in VEX, and moreover that these
map across the entire MDV genome, spanning virus-encoded structural, enzymatic, and regulatory
genes (Figure 6).
As vaccine MDVs typically replicate early (1–2 weeks post-vaccination), and then establish low
levels of latent infection with intermittent periods of virus replication, our data suggest a paradigm
shift in how MD vaccines elicit long-term anti-viral immunity. Our data suggest that vaccine (and/or
perhaps challenge virus-infected cells) are shedding functional viral mRNAs packaged in serum VEX,
and that these may then fuse with antigen presenting cells (APCs) throughout the body, presenting the
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mRNA-encoded peptides in the context of MHC-I, stimulating continual CTL activation in the absence
of overt viremia.
Interestingly, we observed very few MDV proteins in VEX and TEX, save ICP4 (VEX) and
tegument proteins (TEX), described below (Supplementary files S4, S5), suggesting that the main
mechanism of cross-presentation of these antigens to immune cells may be in the functional mRNA
form. Our preliminary in vitro findings indicate exosomal-transfer of functional MDV mRNAs
to recipient chicken macrophages, and we are further validating our findings by treatment of
chicken macrophages with VEX and TEX for the detection of protein expression. The process of
exosomal-transfer of mRNAs to cells in which they become translated has been shown previously,
and has been associated with the maturation state of APCs with which they fuse [65], suggesting that
mature dendritic cells have the greatest affinity and expression of these proteins.
4.4. Proteomic Profiles of VEX and TEX
4.4.1. Potential VEX and TEX Biomarkers
In terms of our proteomic analysis of VEX and TEX, we identified common and exosome
source-specific proteins (Tables 5 and 6 and Supplementary files S6–S8). In terms of VEX-specific
proteins, we identified a number of proteins with putative effects in the regulation of immune responses.
The most consistently identified proteins in this source of VEX were IGFALS and COL221A,
suggesting that they may serve as biomarkers of vaccine-induced protection. Likewise, among
overrepresented proteins identified in TEX, pantetheinase, encoded by the vanin-1 gene, can serve as a
possible serum biomarker for MDV tumor development. Vanin-1 is an enzyme involved in catabolizing
intermediate pantetheine to vitamin B5 for recycling in coenzyme A biosynthesis [66]. Vanin-1 contains
a GPI anchor sequence, is membrane bound on epithelial and myeloid cells, and is a potential
biomarker for certain inflammatory conditions, such as pancreatic cancer associated diabetes (PCAND)
and renal injury [45]. By regulating the synthesis of cysteamine and glutathione, vanin-1 affects
cellular viability, proliferation, and function [67]. In PCAND, neoplastic cells overexpressing vanin-1
displayed greater paraneoplastic islet injury through an increased oxidative stress response. Based
on our data, we propose exosomal pantetheinase may serve as a serum biomarker for MDV-induced
tumor development.
4.4.2. TEX Contain MDV Tegument Proteins
Among MDV proteins identified in TEX, the major tegument protein (MTP) encoded by UL36
(MDV049) gene was detected in TEX of either source (leghorn or broiler) (Supplementary files S4,
S5). MTP is expressed both during lytic and latent infection and encodes an ubiquitin specific
protease (USP) in its N terminus that is conserved among all known herpesviruses [6,68]. A C98A,
protease-dead mutation, in its USP catalytic site, leads to severe reduction in MD tumor incidence,
although MDV replication was unaffected in vitro and in vivo. HSV1 USP was shown to deubiquitinate
poly-ubiquitinated IκBα and mono-ubiquitinated PCNA to inhibit HSV1 DNA-induced IFN-β or
NF-κB activation and DNA damage responses, respectively, to facilitate infection [69,70].
In addition, tegument protein VP13/14 encoded by UL47 was exclusively detected in leghorn
TEX (Supplementary files S4, S5). UL47 is a late gene expressed during lytic infection with very low
and high abundances in CEFs and FFE, respectively [24]. Origins of UL47 in TEX may be due to virus
reactivation from latency and selective exosomal packaging for transfer to distant FFE in order to
promote transmission.
4.4.3. VEX Contain MDV ICP4
Interestingly, the IE transactivator ICP4 was found in low abundances in VEX, but not in TEX.
Syngenic cell-mediated immune responses towards ICP4 was found to be a major factor in defining
the genetic resistance towards MD in B21B21 chickens [9]. Exosomal transfer of ICP4 to APCs and
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the induction of subsequent CTL responses towards conserved ICP4 epitopes appears to be a critical
mechanism in inducing protection against MDV.
4.4.4. Transcription Factor-Associated Pathways in VEX and TEX
Since we found that numerous transcription factors, histones, and DNA-modifying enzymes
were present in both VEX and TEX, we developed models to provide some insight into the potential
effects of these factors on recipient cells. Transcription factor-associated pathway modeling suggested
that there were some TF networks common to VEX and TEX (hepatocyte nuclear factor, HNF1A and
A+T-rich interaction domain, ARID3A, Figure S2, Supplementary files S6–S8), which play important
roles in mouse early embryonic development and maturation of tissues (liver, pancreas and kidney)
and hemopoietic stem cell (HSC) progenitors, respectively [71,72].
VEX-specific transcriptions factors included RREB1, RXRA, and YY1 (Figure S2, Supplementary
file S5). While RREB1 is a proto-oncogene and transcription factor upregulated in several solid tumor
malignancies, but its role in MD lymphoma formation remains unknown [73]. RXRA is a retinoic
acid superfamily nuclear receptor that homo- or heterodimerizes with other nuclear receptors to
mediate a wide range of actions in myeloid cells including chemokine expression, anti-viral Type I
IFN attenuation, phagocytosis of apoptotic cells, and finally, repression of metastasis promoting genes,
suggesting similar roles in MD vaccine mediated protection [74,75].
YY1 is a GLI-kruppel family transcription factor that can activate or deactivate gene expression
depending on binding partners and has a context dependent role as a tumor suppressor or a tumor
growth promoter [76]. In MDV-transformed CD30hi cells, YY1 protein expression was significantly
downregulated compared to CD30lo cells indicating a possible tumor suppressant role [7,76].
Unique to TEX, the MEF2A TF network was identified suggesting a role similar to previously
identified roles of MEF2 family TFs, MEF2A, MEF2B and MEF2D in EBV latency maintenance and
reactivation. MEF2 TFs, through interaction with MEF2 binding motifs in the immediate early (Zta,
Rta) gene promoters maintain them in a silenced state by recruitment of class II histone deacetylases
(HDACs), whereas upon HDAC inhibitor treatment, Zta expression and EBV reactivation results
from MEF2B/D recruitment of histone acetyl transferases and active chromatin modifications of Zta
promoter [77–79].
MEF2 TFs were reported to be expressed in MDV-transformed CD30hi cells in a previous
proteomics study reported by Shack, et al., [7]. Furthermore, in leghorn or broiler TEX, the AP1 family
TF networks involving Jun, Fos, and FosB, and TFs (JunD) themselves were identified, and these are
known to heterodimerize with the MDV oncoprotein Meq to promote cellular transformation [80,81].
5. Main Conclusions
The most compelling finding of our work is the identification of MDV-encoded mRNAs spanning
the entire genome in VEX, at a time when circulating vaccine virus is not readily detectable in PBMC,
suggests a novel mechanism by which CTLs can be continually primed systemically, through fusion
of APCs with VEX and MDV antigen presentation. This report also provides a number of important
data sets for follow-up studies on TEX in Marek’s disease virus-mediated immune suppression and
lymphomagenesis, as well as provides putative mechanisms by which vaccine-associated exosomes
(VEX) may lead to anti-proliferative responses and prolonged, systemic protection from MDV-induced
lymphoma formation.
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